Neuropsychological effects of treatments for adults with cancer: A meta-analysis and review of the literature

被引:212
作者
Anderson-Hanley, C
Sherman, ML
Riggs, R
Agocha, VB
Compas, BE
机构
[1] Glens Falls Hosp, Ctr Canc, Glens Falls, NY USA
[2] Univ Missouri, Kansas City, MO 64110 USA
[3] Inst Canc Res, Kansas City, MO USA
[4] Brown Univ, Sch Med, Providence, RI 02912 USA
[5] Univ Connecticut, Farmington, CT USA
[6] Vanderbilt Univ, Nashville, TN USA
关键词
meta-analysis; cancer; chemotherapy; executive function; verbal memory; motor function;
D O I
10.1017/S1355617703970019
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
A meta-analysis was conducted to evaluate possible neuropsychological effects of treatments for cancer in adults. A search revealed 30 studies, encompassing 29 eligible samples, and leading to inclusion of a total of 838 patients and control participants. A total of 173 effect sizes (Cohen's d) were extracted across 7 cognitive domains and as assessed in the literature via 3 methods of comparison (post-treatment compared with normative data, controls, or baseline performance). Statistically significant negative effect sizes were found consistently across both normative and control methods of comparison for executive function, verbal memory, and motor function. The largest effects were for executive function and verbal memory normative comparisons (-.93 and -.91, respectively). When limiting the sample of studies in the analyses to only those with relatively "less severe" diagnoses and treatments, the effects remained. While these results point toward some specific cognitive effects of systemic cancer therapies in general, no clear clinical implications can yet be drawn from these results. More research is needed to clarify which treatments may produce cognitive decrements, the size of those effects, and their duration, while ruling out a wide variety of possible mediating or moderating variables.
引用
收藏
页码:967 / 982
页数:16
相关论文
共 89 条
[81]  
2-7
[82]   The cognitive effects of recombinant interleukin-2 (rIL-2) therapy: A controlled clinical trial using computerised assessments [J].
Walker, LG ;
Wesnes, KP ;
Heys, SD ;
Walker, MB ;
Lolley, J ;
Eremin, O .
EUROPEAN JOURNAL OF CANCER, 1996, 32A (13) :2275-2283
[83]   NEUROTOXICITY OF COMMONLY USED ANTINEOPLASTIC AGENTS .1. [J].
WEISS, HD ;
WALKER, MD ;
WIERNIK, PH .
NEW ENGLAND JOURNAL OF MEDICINE, 1974, 291 (02) :75-81
[84]   NEUROTOXICITY OF COMMONLY USED ANTINEOPLASTIC AGENTS .2. [J].
WEISS, HD ;
WALKER, MD ;
WIERNIK, PH .
NEW ENGLAND JOURNAL OF MEDICINE, 1974, 291 (03) :127-133
[85]  
WEITZNER MA, 1995, J NEUROPSYCH CLIN N, V7, P347
[86]  
Weitzner MA, 1997, PSYCHO-ONCOL, V6, P169, DOI 10.1002/(SICI)1099-1611(199709)6:3<169::AID-PON269>3.3.CO
[87]  
2-R
[88]   NEUROPSYCHOLOGICAL ASSESSMENT OF COGNITIVE-FUNCTIONING FOLLOWING CHEMOTHERAPY FOR BREAST-CANCER [J].
WIENEKE, MH ;
DIENST, ER .
PSYCHO-ONCOLOGY, 1995, 4 (01) :61-66
[89]   Cognitive function in postmenopausal women treated with raloxifene. [J].
Yaffe, K ;
Krueger, K ;
Sarkar, S ;
Grady, D ;
Barrett-Connor, E ;
Cox, DA ;
Nickelsen, T .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (16) :1207-1213